Targets › PKC
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2027.
Open in Phaseline: the race on PKC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Deciphera Pharmaceuticals | Inlexisertib (DCC-3116) Protein kinase C (PKC) inhibitor | PKC | Phase 1 | GIST | Mar 2027 |
GIST (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.